Payment overview · 2025
General Payments
$461.99
21 reported records · 9 companies
Healthcare provider profile · identity verified
Whitney Lea Walker, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · RIPLEY, MS · NPI 1245638642
Verified facts
What the public records show
CMS Open Payments records show Whitney Lea Walker, FNP received $461.99 in general payments during 2025 across 21 reported records.
Boston Scientific Corporation accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $131.50 | 28.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.27 | 14.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.74 | 13.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.41 | 12.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.52 | 9.4% | 3 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $31.65 | 6.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.52 | 6.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.62 | 4.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.76 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $461.99 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $88.90 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $62.74 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.41 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $48.94 | 3 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $42.60 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.52 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.00 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 111 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
146 | 48 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 291 | 83 |
| Ozempic | Semaglutide | 206 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 182 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 169 | 54 |
| Gabapentin | Gabapentin | 167 | 52 |
| Lisinopril | Lisinopril | 167 | 50 |
| Losartan Potassium | Losartan Potassium | 153 | 44 |
| Eliquis | Apixaban | 152 | 60 |
| Famotidine | Famotidine | 146 | 39 |
| Farxiga | Dapagliflozin Propanediol | 146 | 48 |
| Omeprazole | Omeprazole | 146 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 141 | 45 |
| Ezetimibe | Ezetimibe | 125 | 35 |
| Montelukast Sodium | Montelukast Sodium | 120 | 35 |
| Carvedilol | Carvedilol | 116 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 41 |
| Jardiance | Empagliflozin | 111 | 37 |
| Xarelto | Rivaroxaban | 108 | 33 |
| Meloxicam | Meloxicam | 104 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 31 |
| Furosemide | Furosemide | 89 | 28 |
| Trulicity | Dulaglutide | 77 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 26 |
| Potassium Chloride | Potassium Chloride | 71 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 18 |
| Januvia | Sitagliptin Phosphate | 68 | 21 |
| Metformin Hcl | Metformin Hcl | 68 | 19 |
| Mounjaro | Tirzepatide | 68 | 14 |
| Simvastatin | Simvastatin | 64 | 17 |
| Metformin Hcl Er | Metformin Hcl | 62 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 49 | 15 |
| Fenofibrate | Fenofibrate | 49 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 49 | 16 |
| Entresto | Sacubitril/Valsartan | 47 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 14 |
| Sertraline Hcl | Sertraline Hcl | 47 | 15 |
| Celecoxib | Celecoxib | 45 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 13 |
| Buspirone Hcl | Buspirone Hcl | 42 | 14 |
| Glimepiride | Glimepiride | 42 | 11 |
| Novolog Flexpen | Insulin Aspart | 42 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Linzess | Linaclotide | 41 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 18 |
| Methylprednisolone | Methylprednisolone | 39 | 31 |
| Trazodone Hcl | Trazodone Hcl | 39 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Tradjenta | Linagliptin | 37 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 12 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 29 |
| Azithromycin | Azithromycin | 32 | 30 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 30 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Fluconazole | Fluconazole | 27 | 21 |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 17 |
| Praluent Pen | Alirocumab | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 14 |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Menest | Estrogens,esterified | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $461.99 · 21 records | Boston Scientific Corporation | AIRSUPRA, EMBLEM MRI S-ICD, FREESTYLE LIBRE, FREESTYLE LIBRE 3, Flector, JARDIANCE, Kerendia, LUX-Dx Insertable Cardiac Monitor, Licart, MOUNJARO, NEXLETOL, REPATHA, TRELEGY ELLIPTA, Tirosint | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error